New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENI...(er because it often has no specificsymp...),Health

Date:5/14/2008

er" because it often has no specific symptoms, hypertension increases the risk of cardiovascular and related diseases such as stroke, heart attack, heart failure and kidney disease(4). Of those diagnosed with high blood pressure, 64.9 percent did not have the condition under control(5).

Study Design

The study was a double-blind, randomized, placebo-controlled, parallel-group, multi-center titrate-to-goal study. The primary endpoint was change from baseline in mean SBP at study end. The secondary endpoints included change from baseline in mean DBP, and the percent of patients achieving BP goals of < 140/90, < 130/85, < 130/80 and < 120/80 mm Hg at each titration period and study end and a subgroup analysis by baseline stage of hypertension (Stage 1 and Stage 2). Overall mean baseline BP was 157/94 and 155/94 mm Hg for the active treatment and placebo group, respectively.

The patient population of 465 initially entered a 3-4 week single-blind placebo run-in period. Patients who met inclusion criteria (n=276) were then randomized to receive olmesartan (OM) or placebo according to a titration scheme consisting of a 12-week double-blind study period. Patients randomized to olmesartan initially received 20 mg/day. If BP remained greater than or equal to 120/80 mm Hg, patients were uptitrated until BP was normalized. The titration schedule was as follows: OM 40 mg/day (week 4-6), OM/HCTZ 40/12.5 mg/day (week 7-9), and OM/HCTZ 40/25 mg/day (week 10-12). Once BP was controlled to the target level, patients stayed on the medication dosage that achieved this goal. If at any point, patients BP exceeded 120/80, the titration schedule was resumed.

About BENICAR and BENICAR HCT

Angiotensin II is a hormone that interacts with a receptor on arterial blood vessels, which results in constriction and increasing blood pressure. In addition, angiotensin II stimulates the release of another hormone that causes enhanced sodium and chloride (salt) retentio
'/>"/>

SOURCE Daiichi Sankyo, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
4. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
5. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
6. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
7. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
10. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
11. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer